Wedbush Forecasts Lower Earnings for TScan Therapeutics

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Research analysts at Wedbush decreased their FY2026 earnings estimates for TScan Therapeutics in a research note issued on Tuesday, December 10th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.97) per share for the year, down from their previous forecast of ($0.96). Wedbush currently has a “Outperform” rating and a $7.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ FY2027 earnings at ($1.02) EPS and FY2028 earnings at ($0.94) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.

Several other analysts have also recently issued reports on TCRX. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Wednesday.

TScan Therapeutics Stock Down 5.6 %

Shares of NASDAQ TCRX opened at $2.85 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics has a 1 year low of $2.60 and a 1 year high of $9.69. The stock’s 50-day simple moving average is $4.82 and its 200-day simple moving average is $5.85. The firm has a market cap of $152.11 million, a price-to-earnings ratio of -2.69 and a beta of 0.79.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of Montreal Can purchased a new position in shares of TScan Therapeutics during the 2nd quarter valued at $749,000. Bank of New York Mellon Corp purchased a new stake in shares of TScan Therapeutics during the 2nd quarter worth about $682,000. Great Point Partners LLC bought a new stake in shares of TScan Therapeutics in the 2nd quarter valued at approximately $5,504,000. Marshall Wace LLP increased its holdings in TScan Therapeutics by 60.8% in the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock worth $1,799,000 after buying an additional 116,316 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in TScan Therapeutics during the second quarter valued at approximately $90,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

Insider Activity

In other TScan Therapeutics news, Director Barbara Klencke purchased 5,000 shares of the stock in a transaction dated Monday, September 23rd. The shares were acquired at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the acquisition, the director now owns 45,000 shares of the company’s stock, valued at $238,050. This represents a 12.50 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.76% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.